Correction: STOCKWATCH: Vertex's almost incomplete disclosure
This article was originally published in Scrip
In the previous version of this article it was not stated that the full data set of Vertex's 194 patient clinical study had been reported. This was incorrect as the full data set was released by the company and discussed in a conference call on April 18. That press release included a table showing changes relative to placebo, for the secondary endpoint of FEV1 showing that only the top two doses were significantly different from placebo and the highest doses had a lower efficacy than the second highest doses.
You may also be interested in...
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.